Оптимистичная статья. Тоже хотела ссыль на нее здесь выложить, но Вы меня опередили.😁

Что там если вкратце,? открывает ссылку на не ограниченый доступ к рессурсу

@Tatoha Conclusion I believe that Cassava Sciences has the best risk to reward ratio of any play in the stock market. Simufilam has the potential to be the best selling drug of all time. The question for me is what is the next investment to look into and, for me that is INmune Bio. INmune Bio is also taking a novel approach to AD, both companies use different mechanisms which means they could work in conjunction in the future, and INmune Bio is still in early clinical stages allowing investors to get in early at a good share price and market cap.

Спасибо